Clinical Trial Update: Study Of Abraxane® And Carboplatin As First-Line Treatment For Triple Negative Metastatic Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating Abraxane plus carboplatin as first-line therapy for triple-negative metastatic breast cancer was terminated; results were posted in 201…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer
• Triple-negative Breast Cancer

Drugs mentioned

• Abraxane (paclitaxel albumin-bound)
• CARBOPLATIN (Carboplatin)

Snippet

Sponsor: Duke University | Conditions: Metastatic Breast Cancer | Phase 2 | Status: TERMINATED | Results posted: 2014-12-15